SCHEMBL5485823

SCHEMBL5485823

CONC(=N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cn3)o2)nc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.39
NQO2 P16083 4/20 0.37
PRMT1 Q99873 2/20 0.35
ALDH1A1 P00352 1/20 0.34
TOP1 P11387 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
FAAH O00519 1/20 0.34
RXFP1 Q9HBX9 1/20 0.33
TOP2A P11388 1/20 0.33
TOP2B Q02880 1/20 0.33
P4HA1 P13674 1/20 0.33
P4HTM Q9NXG6 1/20 0.33
MAPK1 P28482 1/20 0.32
BAZ2B Q9UIF8 1/20 0.31
NNMT P40261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5493324 0.93 NQO2 (0.45) APPNQO2PRMT1ALDH1A1TOP1
SCHEMBL5491204 0.84 APP (0.39) APPNQO2PRMT1FAAHRXFP1
SCHEMBL5494996 0.81 P4HTM (0.36) APPNQO2PRMT1ALDH1A1TOP1
SCHEMBL3506390 0.79 FAAH (0.33) APPPRMT1FAAHP4HA1P4HTM
SCHEMBL3505298 0.79 NQO2 (0.52) APPNQO2PRMT1ALDH1A1TOP1
SCHEMBL5492362 0.79 NQO2 (0.47) APPNQO2PRMT1ALDH1A1TOP1
SCHEMBL4353229 0.78 KDM4C (0.40) NQO2PRMT1ALDH1A1TOP1HPGD
SCHEMBL14433310 0.77 NQO2 (0.53) APPNQO2PRMT1ALDH1A1TOP1
SCHEMBL3506268 0.76 NQO2 (0.45) APPNQO2PRMT1ALDH1A1TOP1
SCHEMBL20090626 0.76 HDAC1 (0.47) MAPK1NNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7256203-B2 Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2007-08-14 US disclosed
EP-1565458-A2 DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2005-08-24 EP disclosed
US-20040122015-A1 Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents BOYKIN DAVID W (US) 2004-06-24 US disclosed
WO-2004050018-A2 DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122015-A1 Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents NR0B1, NR2C2, DECR1 APP 4873/4885NQO2 982/4885PRMT1 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.